?
Your prediction
Financial data and news for Corvus
sharewise wants to provide you with the best news and tools for Corvus, so we directly link to the best financial data sources.
Financials
News
Momentum Is Just Starting for These 3 Rapid-Growth Stocks in 2026
Close to one month into 2026, the S&P 500 has been fairly sluggish in the new year, rising by just over 1% overall after multiple dips throughout January. However, that middling performance might
Corvus Pharmaceuticals Director Buys 21,700 Shares. Does This Mean CRVS a Buy?
Immuno-oncology specialist Corvus Pharmaceuticals (NASDAQ:CRVS) reported a recent insider buy amid a year of sharp share price gains.
On June 11, 2026, David Scott Moore, acquired the direct
Boxer Capital’s $18 Million Corvus Pharma Bet Signals Confidence in This Biotech’s Next Phase
On May 15, 2026, Boxer Capital Management disclosed a new position in Corvus Pharmaceuticals (NASDAQ:CRVS), acquiring 1,100,000 shares in the first quarter for an estimated $17.55 million based on
Stock Market Today, Jan. 20: Corvus Pharmaceuticals Surges After Positive Phase 1 Eczema Drug Data
Corvus Pharmaceuticals (NASDAQ:CRVS), an immuno-oncology and dermatology drug developer, closed Tuesday at $21.41, up 165.96%. The stock moved higher after Phase 1 soquelitinib data in atopic